GMP Lentiviral and Retroviral Vector Manufacturing
We don't just manufacture viral vectors,
we help manufacture hope
Accelerating GMP manufacturing of lentiviral and retroviral vectors while pursuing excellence
State-of-the-art 6,400 sq ft MHRA-inspected and licensed GMP facility located in central London
Adherent and suspension cell lines available, initially delivering between 12L and 50L scale
Qualified external Quality Control (QC) release testing vendors to deliver <14-week turnaround times
Two full-time Qualified Persons (QPs) compress wait times to QP certification and release of your viral vector, with a target of 6 months from the start of your campaign
Experienced regulatory submission writers for MHRA, FDA and EMA filings
Technology transfer support for process scale-out to commercial manufacturers
“We manufacture viral vectors using adherent and suspension cell lines.”
“We rely on the principles of quality, standardization and robustness of processes to ensure that your product is safe for patients.”